BSC 2201
Alternative Names: BSC-2201Latest Information Update: 06 Jul 2023
At a glance
- Originator Asan Medical Center; BiSiChem
- Developer BiSiChem
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 27 Jun 2023 BSC 2201 is available for licensing as of 27 Jun 2023. https://bisichem.com/default/#about (BiSiChem website, June 2023)
- 27 Jun 2023 Early research in Cancer in South Korea (unspecified route) before June 2023 (BiSiChem pipeline, June 2023)
- 31 Aug 2021 BiSiChem enters into a collaboration with Asan Medical Center for cancer immunotherapy (BiSiChem pipeline, June 2023)